Invokana vs. Glimepiride

See how Invokana and Glimepiride compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Invokana is an SGLT2 inhibitor with added FDA approvals for heart and kidney protection, while glimepiride is a sulfonylurea used only for blood sugar control.

  • Glimepiride carries a real risk of hypoglycemia and costs far less than Invokana, while Invokana carries risks of genital infections and lower limb amputation.

  • Both drugs are taken by mouth once daily, but only Invokana has FDA-backed evidence of reducing cardiovascular events and slowing kidney disease.

Invokana vs. Glimepiride Drug Summary

Invokana

Invokana (canagliflozin) is an SGLT2 inhibitor for adults and children age 10 and older with type 2 diabetes. It is taken as a single tablet by mouth once daily, starting at 100 mg and increasing to 300 mg if more blood sugar control is needed. Beyond glycemic control, it is also approved to reduce cardiovascular and kidney complications in certain patients.

Glimepiride

Glimepiride is a sulfonylurea tablet used as an add-on to diet and exercise for type 2 diabetes. It is taken once daily by mouth, usually starting at 1 mg and increasing gradually to a maximum of 8 mg if more blood sugar control is needed. It has been used since 1995 and lowers blood sugar by prompting the pancreas to release more insulin.

Invokana vs. Glimepiride Side Effects

Invokana

Most common
genital yeast infection (up to 11%)
urinary tract infection (up to 6%)
increased urination (up to 5%)
male genital yeast infection (up to 4%)

Glimepiride

Most common
hypoglycemia (>5%)
dizziness (>5%)
asthenia (>5%)
headache (>5%)

Invokana vs. Glimepiride Dosage

Invokana

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 100 mg once daily At the start
Maximum dose 100 mg once daily Same as starting
Dose changes None Fixed dose

Glimepiride

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1 mg once daily At the start
Maximum dose 8 mg once daily If needed
Dose changes 3 increases As tolerated

Invokana vs. Glimepiride Indications

Invokana

Invokana is an SGLT2 inhibitor approved to improve blood sugar control in adults and children age 10 and older with type 2 diabetes. It also carries specific approvals to lower cardiovascular risk in adults with heart disease and to slow kidney disease progression in those with diabetic nephropathy. It is not approved for type 1 diabetes or diabetic ketoacidosis.

  • Adjunct to diet and exercise for blood sugar control in type 2 diabetes

  • Reduces risk of heart attack, stroke, and cardiovascular death in adults with known heart disease

  • Reduces risk of kidney failure, heart failure hospitalization, and cardiovascular death in diabetic kidney disease

  • Approved for children age 10 and older with type 2 diabetes

  • Not approved for type 1 diabetes or diabetic ketoacidosis

Glimepiride

Glimepiride is a sulfonylurea approved as an add-on to diet and exercise to help control blood sugar in adults with type 2 diabetes. Unlike newer diabetes medicines such as Invokana, its FDA label does not claim any proven heart or kidney benefit. It is not approved for type 1 diabetes or diabetic ketoacidosis.

  • Adjunct to diet and exercise for blood sugar control in type 2 diabetes

  • No FDA-recognized cardiovascular or kidney protection benefit

  • One of the oldest oral diabetes medicines, FDA-approved since 1995

  • Must be stopped at least two weeks before expected delivery

  • Not approved for type 1 diabetes or diabetic ketoacidosis

Invokana vs. Glimepiride Pros and Cons

Invokana

Invokana carries FDA approvals beyond blood sugar control, including reducing cardiovascular and kidney complications, which most oral diabetes pills cannot claim. It carries a warning for increased lower limb amputation risk, and genital yeast infections are common. Most insurance plans cover it, though the list price is far higher than older generic options.

Pros

  • Proven to reduce heart attack, stroke, and cardiovascular death in patients with heart disease

  • Only oral diabetes pill FDA-approved to slow diabetic kidney disease progression

  • Can support modest weight loss alongside blood sugar control

  • Very low risk of hypoglycemia when used alone

Cons

  • Higher risk of genital yeast infections and urinary tract infections

  • Carries an FDA warning for increased lower limb amputation risk

  • Not recommended once kidney function drops below a certain level

  • Costs roughly $550 to $830 per month without insurance

Glimepiride

Glimepiride is one of the least expensive type 2 diabetes medicines available, with decades of clinical use behind it. It lowers blood sugar effectively, but carries a real risk of low blood sugar episodes and lacks FDA-recognized heart or kidney benefits. Older sulfonylureas like this one also carry an FDA warning about a possible increase in cardiovascular death.

Pros

  • Costs roughly $10 to $20 per month, among the cheapest diabetes drugs available

  • Long track record of use since its FDA approval in 1995

  • Simple once-daily oral dosing with no injections involved

  • Works quickly to bring blood sugar down

Cons

  • Meaningful risk of hypoglycemia, especially with missed or delayed meals

  • FDA warning about a possible increase in cardiovascular mortality with sulfonylureas

  • No proven cardiovascular or kidney protective benefit

  • Risk of hemolytic anemia in patients with G6PD deficiency

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.